Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy
NCT04133207 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 340
Last updated 2021-02-12
Summary
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with CDKi in patients with HR-positive, HER2-negative advanced breast cancer.
Conditions
- Breast Cancer Stage IV
Sponsors & Collaborators
-
Hellenic Cooperative Oncology Group
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-01
- Primary Completion
- 2019-08-01
- Completion
- 2021-01-02
Countries
- Greece
Study Locations
More Related Trials
-
A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
NCT06791161 ·Status: ENROLLING_BY_INVITATION
-
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients
NCT01232062 ·Status: COMPLETED
-
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO
NCT03227328 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
NCT06996093 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755 ·Status: RECRUITING
-
Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients
NCT05755581 ·Status: UNKNOWN ·Phase: PHASE1
-
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT03439735 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344793 ·Status: COMPLETED
-
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283 ·Status: RECRUITING ·Phase: PHASE1
-
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
NCT00963729 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
NCT06176534 ·Status: RECRUITING ·Phase: PHASE2
-
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
NCT01327781 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
NCT06970912 ·Status: RECRUITING ·Phase: PHASE2
-
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
NCT04753177 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
NCT02789332 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
NCT07290166 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00003352 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
NCT00668616 ·Status: COMPLETED ·Phase: PHASE3
-
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
NCT01061359 ·Status: COMPLETED
-
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
NCT00872625 ·Status: COMPLETED ·Phase: PHASE1
-
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089 ·Status: COMPLETED ·Phase: NA
-
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
NCT00645866 ·Status: COMPLETED ·Phase: PHASE2